经典名方辛夷散治疗肺虚感寒型鼻鼽的临床研究

Clinical Study on the Classic Prescription Xinyi Powder in Treating Allergic Rhinitis with Lung Deficiency Related Cold

    摘要
  • 摘要:
    目的 探讨经典名方辛夷散治疗肺虚感寒型鼻鼽患者的临床疗效及其可能的作用机制。
    方法 选取2023年1月至2024年7月江苏省中医院耳鼻喉科门诊符合肺虚感寒型鼻鼽纳入标准的189例患者，随机分为试验组(n=126)和对照组(n=63)，对照组采用氯雷他定口服治疗，试验组服用辛夷散。治疗前后比较2组患者TNSS、TNNSS评分及中医证候积分以综合评价临床疗效，通过鼻部VAS、RQLQ评分多维度评价患者生活质量的变化，ELISA法检测血清IL-4、IL-5、IgE、SP、CGRP表达水平变化情况。
    结果 治疗14 d后，2组患者TNSS、TNNSS、VAS、RQLQ评分及中医证候积分均降低(P < 0.01)；试验组在改善患者鼻塞、流涕、鼻涕倒流、眼痒等伴随症状优于对照组(P < 0.05，P < 0.01)，同时可更显著改善患者畏风怕冷、自汗气短、咳嗽痰稀症状(P < 0.01)，RQLQ总评分明显优于对照组(P < 0.01)；治疗后，2组患者血清IL-4、IL-5、IgE、SP、CGRP水平均明显降低(P < 0.01)，2组间无统计学差异。
    结论 辛夷散能显著减轻肺虚感寒型鼻鼽患者鼻部症状及全身伴随症状，明显改善患者的生活质量，可能是通过抑制炎性因子及神经肽的表达，调节神经免疫而发挥治疗作用。

     

    Abstract:
    OBJECTIVE To explore the clinical efficacy and possible mechanism of the classic prescription Xinyi Powder in the treatment of allergic rhinitis with lung deficiency related cold.
    METHODS A total of 189 patients who met the inclusion criteria of allergic rhinitis with lung deficiency related cold in the otolaryngology clinic of Jiangsu Province Hospital of Chinese Medicine from January 2023 to July 2024 were selected and randomly divided into the experimental group (n=126) and the control group (n=63). The control group was treated with oral loratadine, and the experimental group took Xinyi Powder. Before and after treatment, the TNSS, TNNSS scores and TCM syndrome scores of the two groups of patients were compared to comprehensively evaluate the clinical efficacy. The changes in the patients' quality of life were evaluated in multiple dimensions using nasal VAS and RQLQ scores. The changes in serum IL-4, IL-5, IgE, SP and CGRP expression levels were detected by ELISA.
    RESULTS After 14 days of treatment, the TNSS, TNNSS, VAS, RQLQ scores and TCM syndrome scores of the two groups of patients were reduced (P < 0.01); the experimental group was better than the control group in improving the concomitant symptoms such as nasal congestion, runny nose, postnasal drip, and itchy eyes (P < 0.05, P < 0.01), and it could also significantly improve the symptoms of fear of wind and cold, spontaneous sweating, shortness of breath, and cough with thin sputum (P < 0.01), and the total RQLQ score was significantly better than the control group (P < 0.01). After treatment, the serum IL-4, IL-5, IgE, SP, and CGRP levels of the two groups of patients were significantly reduced (P < 0.01), and there was no statistical difference between the two groups.
    CONCLUSION Xinyi Powder can significantly alleviate the nasal symptoms and systemic concomitant symptoms of patients with allergic rhinitis of lung deficiency and cold type, and significantly improve the quality of life of patients. It may play a therapeutic role by inhibiting the expression of inflammatory factors and neuropeptides and regulating neuroimmunity.

     

    • HTML全文
    • 参考文献(20)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回